BiomX Inc. is a U.S.-listed biotechnology company focused on developing bacteriophage-based therapies for serious bacterial infections. Its reported pipeline has centered on BX011 for diabetic foot infections and earlier programs including BX004, which was discontinued in 2025. The company’s Israeli operating subsidiary, BiomX Ltd., entered insolvency proceedings in December 2025, materially reducing the group’s operating capacity and leaving BiomX Inc. with limited ongoing operations. As a result, the company is actively evaluating strategic alternatives and other business opportunities while seeking additional financing and control of its remaining assets and expertise.
0.87
0.87
| % | |
|---|---|
| Clinical-stage phage therapeutics | 80% Drug candidates designed to treat bacterial infections using bacteriophages, including BX011 and the discontinued BX004 program. |
| Platform discovery and R&D | 15% Internal phage discovery, engineering, and translational research used to generate new therapeutic candidates. |
| Licensing and collaboration | 5% Potential technology licenses, research collaborations, and related milestone or grant-based income. |
BiomX does not currently sell approved products, so its direct customer base is not commercial end-users but rather...
Hospitals, wound-care centers, and physicians would buy approved phage therapies if the company reaches commercialization, because these infections are clinically difficult and often resistant to standard antibiotics.
Biopharma collaborators may license BiomX technology or co-develop candidates to share development risk and access the phage platform.
Public innovation bodies fund preclinical and clinical work through grants, helping offset R&D spend and extend runway.
Equity and preferred-stock investors finance operations because the company has no product revenue and depends on external capital.
BiomX is headquartered in the United States, but its historical operating base has been in Israel through BiomX Ltd...
BiomX’s near-term strategy is centered on preserving liquidity, pursuing strategic alternatives, and determining...
The insolvency of BiomX Ltd. and limited remaining operations make asset monetization, restructuring, or a business pivot the central near-term priority.
The company has no product revenue and depends on external capital to continue any R&D or corporate activity.
Clinical progress is necessary to create any future commercial or partnering value from the platform.
BiomX faces severe company-specific execution risk because its Israeli operating subsidiary entered insolvency...
The core operating subsidiary entered insolvency proceedings, reducing workforce, R&D continuity, and the company’s ability to advance programs.
With no product sales and limited liquidity, the company may need additional capital or may be unable to continue operations.
Phage candidates may fail due to efficacy, safety, or regulatory hurdles, which is common in biotech development.
Other phage and anti-infective developers may reach the market first or with superior data, reducing BiomX’s relevance.
Historical operations and personnel were concentrated in Israel, creating exposure to local conflict and disruption.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
ORMP · Pharmaceutical Preparations
BMRA · In Vitro & In Vivo Diagnostic Substances
IBO · Pharmaceutical Preparations
BIXT · Pharmaceutical Preparations
BMEA · Pharmaceutical Preparations
: 11/08/2026